The Journal of Clinical Endocrinology & Metabolism · 1974 · 202 citations · 0 references
MedicineEndocrinologyPharmacotherapyClinical PharmacologyEndocrine PharmacotherapyHormone BiochemistryGrowth HormoneGrowth Hormone RegulationPituitary DisordersPituitary Gland FunctionPituitary Hormone RegulationPituitary HormonesGrowth Hormone MeasurementHypothalamic-pituitary-growth AxisSingle-dose Administration
A single oral dose of 2–Br–α–ergocryptine (CB154) lowers considerably plasma GH levels in 7 acromegalic patients. The effect is present 2 hrs following the ingestion and lasts about 4–5 hrs.